Status:
RECRUITING
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
Lead Sponsor:
Assiut University
Conditions:
Myasthenia Gravis
Autoimmune Diseases of the Nervous System
Eligibility:
All Genders
16+ years
Brief Summary
This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG. The predictors are i...
Detailed Description
Myasthenia gravis (MG) is a rare acquired autoimmune disease affecting the neuromuscular junction (NMJ), caused by autoantibodies that target the post-synaptic membrane. It's overall prevalence ranged...
Eligibility Criteria
Inclusion
- Age from 16 years and older.
- Gender: both sexes are included.
- Clinical Diagnosis of MG with supporting evidence as:
- unequivocal clinical response to pyridostigmine
- decrement \>10% in repetitive nerve stimulations study (RNS).
- Willingness to sample collection, imaging study and other disease-related examinations and assessments.
Exclusion
- Age younger than 16 years.
- History of chronic psychiatric or neurological disorder other than MG that can produce weakness or fatigue.
- Severe systemic illness affecting life-expectancy.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05214612
Start Date
January 1 2022
End Date
March 31 2025
Last Update
July 31 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University
Asyut, Egypt, 71515